topoisomerase I, Topoisomerase II, DNA gyrase, Topoisomerase III

High purity eukaryotic and prokaryotic DNA topoisomerases and NEW for 2005, Tdp1, Mutated Human Topo I, and Recombinant Human Baculovirus Topo I.

Tdp-1 is a new and exciting topo related drug target. This enzyme, recently discovered first in yeast and then in humans, is responsible for removing topo from the covalent damage complexes that form after treating cells with topoisomerase poisons. At the present time, there have been no specific drugs that target Tdp1; however, this is a very hot and actively investigated area.

TopoGEN now offers the following Tdp1 products:

Cat #2004: Purified Tdp1
Cat #1004: Tdp1 Assay Kit.

References

Interthal, H., Pouliot, J. and Champoux, J., 2001. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. PNAS 98: 12009-12014

Yang, S., Burgin, A, Huizenga, B., Robertson, C, Yao, K., and Nash, H. 1996. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topisomerases. PNAS 93:11534-11539

Price reduction on DNA Gyrase! Visit our Price List for further details.

[DNA Gyrase] [Topo II (p170)] [E. coli Topo IV] [Tdp1] [Mutated Human Topo I] [Recombinant Human Topo I]

We offer custom screening on a contract basis. Let us test your compounds for topo targeting activity.